Peter Schraml
Overview
Explore the profile of Peter Schraml including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
3145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Angori S, Lakshminarayanan H, Banaei-Esfahani A, Muhlbauer K, Bolck H, Kallioniemi O, et al.
Int J Cancer
. 2024 Dec;
156(7):1457-1469.
PMID: 39707614
Papillary renal cell carcinoma (pRCC) is the second most frequent renal cancer subtype but has no indicated targeted treatments. MET inhibition may be a treatment for MET-driven pRCC, but there...
2.
van Rijthoven M, Obahor S, Pagliarulo F, van den Broek M, Schraml P, Moch H, et al.
Commun Med (Lond)
. 2024 Jan;
4(1):5.
PMID: 38182879
Background: Tertiary lymphoid structures (TLSs) are dense accumulations of lymphocytes in inflamed peripheral tissues, including cancer, and are associated with improved survival and response to immunotherapy in various solid tumors....
3.
Batavia A, Rutishauser D, Sobottka B, Schraml P, Beerenwinkel N, Moch H
Mod Pathol
. 2023 Apr;
36(8):100194.
PMID: 37088333
Approximately 70% of clear cell renal cell carcinoma (ccRCC) is characterized by the biallelic inactivation of von Hippel-Lindau (VHL) on chromosome 3p. ELOC-mutated (Elongin C-mutated) renal cell carcinoma containing biallelic...
4.
Schraml P, Aimi F, Zoche M, Aguilera-Garcia D, Arnold F, Moch H, et al.
J Pathol Clin Res
. 2023 Mar;
9(4):273-284.
PMID: 36999983
ADP-ribosylation (ADPR) of proteins is catalyzed by ADP-ribosyltransferases, which are targeted by inhibitors (i.e. poly(ADP-ribose) polymerase inhibitors [PARPi]). Although renal cell carcinoma (RCC) cells are sensitive in vitro to PARPi,...
5.
Krishnan A, Spegg V, Dettwiler S, Schraml P, Moch H, Dedes K, et al.
Mod Pathol
. 2023 Mar;
36(7):100167.
PMID: 36990278
PARP inhibitors (PARPi) are increasingly used in breast cancer therapy, including high-grade triple-negative breast cancer (TNBC) treatment. Varying treatment responses and PARPi resistance with relapse currently pose limitations to the...
6.
Angori S, Banaei-Esfahani A, Muhlbauer K, Bolck H, Kahraman A, Karakulak T, et al.
Eur Urol Focus
. 2023 Mar;
9(5):751-759.
PMID: 36933996
Background: Immune checkpoint inhibitors and antiangiogenic agents are used for first-line treatment of advanced papillary renal cell carcinoma (pRCC) but pRCC response rates to these therapies are low. Objective: To...
7.
Fischer J, Jackson H, de Souza N, Varga Z, Schraml P, Moch H, et al.
Cell Rep Med
. 2023 Mar;
4(3):100977.
PMID: 36921599
Although breast cancer mortality is largely caused by metastasis, clinical decisions are based on analysis of the primary tumor and on lymph node involvement but not on the phenotype of...
8.
Varga Z, Christiansen A, Lukamowicz-Rajska M, Batavia A, von Teichman A, Schraml P, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428702
Primary systemic or neoadjuvant chemotherapy of breast cancer has become a standard therapy option in locally advanced or predefined intrinsic subtypes such as triple negative or Her2 positive breast cancer....
9.
Aboouf M, Armbruster J, Thiersch M, Guscetti F, Kristiansen G, Schraml P, et al.
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232784
The expression of myoglobin (MB), well known as the oxygen storage and transport protein of myocytes, is a novel hallmark of the luminal subtype in breast cancer patients and correlates...
10.
Erlmeier F, Sun N, Shen J, Feuchtinger A, Buck A, Prade V, et al.
Oncology
. 2022 Oct;
101(2):126-133.
PMID: 36198279
Background: Correct tumor subtyping of primary renal tumors is essential for treatment decision in daily routine. Most of the tumors can be classified based on morphology alone. Nevertheless, some diagnoses...